Potential Mechanisms of COX-2 Selective Inhibitors Affecting Cardiovascular Risk

REFERENCES

• Smith WL, DeWitt DL, Garvavito RM. Cyclooygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000; 69: 145–82.
   PubMed Web of Science ®Google Scholar
• Simmons DL, Botting RM, Robertson OM, et al. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid anti-inflammatory drugs. Proc Nat Acad Sci. USA. 1999; 96: 3275–80.
   PubMed Web of Science ®Google Scholar
• Yu Y, Fan J, Chen X-S, et al. Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nature Medicine. 2006; 12: 699–704.
   PubMedGoogle Scholar
• Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071–80.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L. Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343: 1520–28.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092–1102.
   PubMed Web of Science ®Google Scholar
• Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors pareoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac. Cardiovasc Surg. 2003; 125: 1481–92.
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Nussen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286: 954–9.
   PubMed Web of Science ®Google Scholar
• Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circularion. 2006: 113: 2906–13.
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennett JS, Daugherty A, et al. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians. A Scientific Statement from the American Heart Association. Circulation. 2007; 115: 1634–42.
   Google Scholar
• Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost. 2006; 96: 393–400.
   PubMed Web of Science ®Google Scholar
• Nulton-Persson AC, Sweda LI, Sadek HA. Inhibition of Cardiac Mitochnodrial Respiration by Salicylic Acid and Acetylsalicylate. J Cardiovascular Pharmacol. 2004; 44: 591–5.
   PubMed Web of Science ®Google Scholar
• McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX) -2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999; 96: 272–7.
   PubMed Web of Science ®Google Scholar
• Belton O, Byrne D, Kearney D, et al. Cyclooxygenase- 1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000; 102: 840–5.
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003; 2: 879–90.
   PubMed Web of Science ®Google Scholar
• Cipollone F, Rocca B, Patrono C. Cyclooxygenase- 2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 2004; 24: 246–55.
   PubMed Web of Science ®Google Scholar
• Schrör K. Prostacyclin (Prostaglandin I2) and atherosclerosis. In: Rubanyi GM, Dzau VJ, eds. The Endothelium in Clinical Practice. New York, NY: Marcel Dekker; 1998: 1–44.
   Google Scholar
• Zimmermann N, Wenk A, Kim U-H, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary bypass surgery. Circulation. 2003; 108: 542–7.
   PubMed Web of Science ®Google Scholar
• Weber A-A. Aspirin and activated platelets. In: Curtis-Prior P, ed Prostaglandins and Eicosanoids. London, UK: John Wiley & Sons; 2004: 373–85.
   Google Scholar
• Bunting S, Moncada S, Vane JR. The prostacyclin- thromboxaneA2 balance: Pathophysiologocal and therapeutic implications. Br Med Bull. 1983; 39: 271–6.
   PubMed Web of Science ®Google Scholar
• Caughry GE, Cleland LG, Gamble JR, et al. Up-regulation of endothelial cyclooxugenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem. 2001; 276: 37839–45.
   Google Scholar
• Dogne JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci. 2005; 12: 639–44.
   Google Scholar
• Pitt B, Shea MJ, Romson JL, et al. Prostaglandins and prostaglandin inhibitors in ischemic heart disease. Ann Int Med. 1983; 99: 83–92.
   PubMedGoogle Scholar
• Ruan KH, Dogne JM. Implication of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designs. Curr Pharm Des. 2006; 12: 925–41.
   Google Scholar
• Dogne JM, Hanson J, de Leval X, et al. From the design to the clniical application of thromboxane modulators. Curr Pharm Des. 2006; 12: 903–23.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296: 539–41.
   PubMed Web of Science ®Google Scholar
• Dai W, Kloner RA. Relationship between cyclooxygenase- 2 inhibition and thrombogenesis. J Cardiovasc Pharmacol Therapeut. 2004; 9: 51–9.
   Google Scholar
• Patrignani P, Sciulli MG, Manarini S, et al. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol. 1999; 50: 661–7.
   PubMed Web of Science ®Google Scholar
• Meyer CH, Schmidt JC, Rodrigues EB, et al. Risk of retinal vein occlusions in patients treated with rofecoxib (Vioxx). Ophthalmologica. 2005; 219: 243–7.
   PubMedGoogle Scholar
• Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006; 116: 1391–9.
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritic Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004; 364: 675–84.
   PubMed Web of Science ®Google Scholar
• Buerkle MA, Lehrer S, Sohn H-Y, et al. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circ. 2004. 110: 2053–9.
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Lucas R, Vojnovic I, et al. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. The FASEB Journal. 2006; 20: 2468–75.
   PubMed Web of Science ®Google Scholar
• Boutaud O, Aronoff DM, Richardson JH, et al. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc Natl Acad Sci. U.S.A. 2002; 99: 7130–5.
   PubMed Web of Science ®Google Scholar
• Lucas R, Warner TD, Vojnovic I, et al. Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. FASEB J, 2005; 19: 635–7.
   PubMed Web of Science ®Google Scholar
• Gierse JK, Koboldt CM, Walker MC, et al. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J. 1999; 339: 607–14.
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Boyce S, et al. Biochemical and pharmacaological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997; 121: 105–17.
   PubMed Web of Science ®Google Scholar
• Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res. 2005; 96: e1–e6.
   PubMed Web of Science ®Google Scholar
• Esmon, CT. Protein C, Protein S, and Thrombomodulin. In: Colman RW, Hirsch J, Marder VJ, Clowes AM, George JN, eds. Hemostasis and Thrombosis. Basic principles and clinical practice. Philadelphia, PA: Lipincott, Williams and Wilkins; 2001: 335–53.
   Google Scholar
• Laszik ZG, Zhou XJ, Ferrell GL, et al. Downregulation of endothelial expression of endothelial cellprotein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol. 2001; 159: 797–802.
   PubMed Web of Science ®Google Scholar
• Wu KK, Aleksic N, Ballantyne CM, et al. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in prediciting risk or coronary heart disease. Circulation. 2003; 107: r66–r69.
   Google Scholar
• Smith HS. COX-2 inhibitor-induced ischemic deconditioning theory. Presented at the Capital District Pain Conference August 2005. Albany, NY.
   Google Scholar
• Shinmura K, Tang X, Wang Y, et al. Cyclooxygenase- 2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA. 2000; 97: 10197–202.
   PubMed Web of Science ®Google Scholar
• Shinmura K, Xuan YT, Tang XL, et al. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res. 2002; 90: 602–8.
   Google Scholar
• Miki T, Cohen MV, Downey JM. Opioid receptor contributes to ischemic preconditioning through protein kinases C activation in rabbits. Mol Cell Biochem. 1998; 186: 3–12.
   PubMed Web of Science ®Google Scholar
• Dowd NP, Scully M, Adderlay SR, et al. Inhibition of cuclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest. 2001; 108: 585–90.
   PubMed Web of Science ®Google Scholar
• Yokoyama C, Yabuki T, Inoue H, et al. Human gene encoding prostacyclin synthase (PTGIS): genomic organization, chromosomal localization, and promoter activity. Genomics. 1996; 36: 296–304.
   PubMed Web of Science ®Google Scholar
• Shinmura K, Maiko N, Tamaki K, et al. COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts. Am J Phsyiol. 2002; 283: H2534–43.
   PubMed Web of Science ®Google Scholar
• Xuan YT, Tang XL, Banerjee S, et al. Nuclear factor-kappa ??plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res. 1999; 84: 1095–1109.
   PubMed Web of Science ®Google Scholar
• McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic bisosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999; 96: 272–7.
   PubMed Web of Science ®Google Scholar
• Belton O, Byrne D, Kearney D, et al. Cyclooxygenase- 1 and -2 dependent prostacyclin formation I patients with atherosclerosis. Circulation. 2000; 102: 840–5.
   PubMed Web of Science ®Google Scholar
• Numaguchi Y, Harada M, Osanai H, et al. Altered gene expression of prostacyclin synthase and prostacyclin receptor in the thoracic aorta of spontaneously hypertensive rates. Cardiovasc Res. 1999; 41: 682–8.
   PubMed Web of Science ®Google Scholar
• Narumiya S, Sugimotot Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999; 79: 1193–1226.
   PubMed Web of Science ®Google Scholar
• Simpson PJ, Mickelson J, Fantone JC, et al. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA. 2000; 97: 10197–202.
   Google Scholar
• Xiao CY, Hara A, Yuhki K, et al. Roles of prostglandin I2 and thromboxane A2 in cardiac ischemicreperfusion injury: a study using mice lacking their respective receptors. Circulation. 2001; 104: 2210–5.
   PubMed Web of Science ®Google Scholar
• Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem. 1999; 274: 5038–46.
   PubMed Web of Science ®Google Scholar
• Dowd NP, Scully M, Adderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest. 2001; 108: 585–90.
   PubMed Web of Science ®Google Scholar
• Araki H, Lefer AM. Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart. Circ Res. 1980; 47: 757–63.
   PubMed Web of Science ®Google Scholar
• Shinmura K, Tamaki K, Sata T, et al. Prostacyclin attenuates oxidate damage of myocytes by opening mitochondrial ATP-sensitive K + channels via the EP3 receptor. Am J Phsiol Heart Circ Phsiol. 2004; 228: H2093–H2101.
   Google Scholar
• Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol. 2001; 41: 661–90.
   PubMed Web of Science ®Google Scholar
• Hohfeld T, Zucker TP, Meyer J, et al. Expression, function, and regulation of E-type prostaglandin receptors (EP3) in the nonschemic and ischemic pig heart. Circ Res. 1997; 81: 765–73.
   Google Scholar
• Zacharowski K, Olbrich A, Piper J, et al. Selective activation of the prostanoid EP3 receptor reduces myocardial infarct size in rodents. Aeterioscler Thromb Vasc Biol. 1999; 19: 2141–7.
   Google Scholar
• Hohlfeld T, Meyer-Kirchrath J, Vogel YC, et al. Reduction of infarct size by selective stimulation of prostaglandin EP3 receptors in the reperfused iscjemic pig heart. J mol Cell Cardiol. 2000; 32: 285–96.
   PubMed Web of Science ®Google Scholar
• Niederberger E, Manderscheid C, Grösch S, et al. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol. 2004; 68: 341–50.
   PubMed Web of Science ®Google Scholar
• Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappa B. FASEB J. 2001; 15: 1622–4.
   PubMed Web of Science ®Google Scholar
• Niederberger E, Tegeder I, Schafer C, et al. Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation. J Pharmocaol Exp Ther. 2003; 304: 1153–60.
   PubMed Web of Science ®Google Scholar
• Safer ME. New Problems raised by increased pulse pressure. Eur Heart J. 2005; 26: 2081–2.
   Google Scholar
• Egan KM, Lawson JA, Fries S, et al. COX-2 derived prostacyclin confers atheroprotection on female mice. Science. 2004; 306: 1954–7.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Tahara Y, Mataumoto M, et al. Roles of thromboxane A (2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004; 114: 784–94.
   PubMed Web of Science ®Google Scholar
• Safar ME, Girerd X, Laurent S. Structural changes of large conduit arteries in hypertension. J Hypertens. 1996; 14: 545–55.
   PubMed Web of Science ®Google Scholar
• Lim TT, Liang DH, Botas J, et al. Role of compensatory enlargement and shrinkage in transplant coronary artery disease. Serial intravascular ultrasound study. Circulation. 1997; 95: 855–9.
   Google Scholar
• Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005; 2: 201–7.
   PubMed Web of Science ®Google Scholar
• Rudic DR, Brinster D, Cheng Y, et al. COX-2 derived prostacyclin modulates vascular remodeling. Circ Res. 2005; 96: 1240–7.
   PubMed Web of Science ®Google Scholar
• Smith HS, Baird W. Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population. Am J Hosp Palliat Care. 2003; 20: 149–54.
   Google Scholar
• Steffel HJ, Hermann M, Greitert H. Celecoxib decreases endothelial tissue factor expression through inhibration of c-Jun terminal NH2 kinase phosphorylation. Circ. 2005; 111: 1685–9.
   PubMed Web of Science ®Google Scholar
• Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardovasc Res. 2002; 53: 313–25.
   PubMed Web of Science ®Google Scholar
• Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003; 107: 973–7.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Brown NJ, Vaughn DE, et al. Established and emerging biomarkers in the prediction of first athero, thrombotic events. Circ. 2004; 109: IV6-IV19.
   Google Scholar
• Hurlimann D, Enseleit F, Ruschitzka F. [Rheumatoid Arthritis, Infflammation, and Atherosclerosis]. 1 Herz. 2004; 29: 760–8.
   Google Scholar
• Wassmann S, Stumpf M, Strehlow K, et al. Interleukin-6 indices oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type I receptor. Circ Res. 2004; 94: 534–41.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Vignoli A, Bani MR, et al. Alltrans retinoic acid modulates microvascular endothelial cell hemostatic properties. Haematologica. 2003; 88: 895–905.
   PubMedGoogle Scholar
• Muhlfelder TW, Teodorescu V, Rand J, et al. Human atheromatous plaque extracts induce tissue factor activity (TFa) in monocytes and also express constitutive TFa. Thromb Haemost. 1999; 81: 146–50.
   Google Scholar
• Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost. 1995; 74: 90–3.
   Google Scholar
• Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003; 9: 458–62.
   PubMed Web of Science ®Google Scholar
• Szotowski B, Antoniak S, Poller W, et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res. 2005; 96: 1233–9.
   PubMed Web of Science ®Google Scholar
• Moons AH, Levi M, Peters RJ. Tissue factor and coronary aetery disease. Cardiovasc Res. 2002; 53: 313–25.
   PubMed Web of Science ®Google Scholar
• Viles-Gonzalez JF, Anand SX, Zafar MU, et al. Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis. J Cardiovasc Pharmacol. 2004; 43: 669–76.
   Google Scholar
• Felmeden DC, Spencer CGm Chung NA, et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT])/ Am J Cardiol. 2003; 92: 400–5.
   Google Scholar
• Blann AD, Amiral J, McCollum CN, et al. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls. Atheroscleosis. 2000; 152: 29–34.
   PubMed Web of Science ®Google Scholar
• Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2003; 109: 2524–8.
   Google Scholar
• Makin AJ, Chung NA, Silverman SH, et al. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci (Lond). 2003; 104: 397–404.
   Google Scholar
• Ardissino D, Merlini PA, Ariens R, et al. Tissue factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997; 349: 769–71.
   PubMed Web of Science ®Google Scholar
• Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 1999; 99: 2908–13.
   PubMed Web of Science ®Google Scholar
• Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfon amide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004; 177: 235–43.
   PubMed Web of Science ®Google Scholar
• Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol. 1998; 9: 441–8.
   PubMed Web of Science ®Google Scholar
• Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. JBiol Chem. 1997; 272: 20963–6.
   PubMed Web of Science ®Google Scholar
• Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002; 22: 1649–54.
   PubMed Web of Science ®Google Scholar
• Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003; 107: 405–9.
   PubMed Web of Science ®Google Scholar
• Hermann M, Camici G, Fratton A, et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation. 2003; 108: 2308–11.
   PubMed Web of Science ®Google Scholar
• Griendling KK, Sorescu D, Lassegue B, et al. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000; 20: 2175–83.
   PubMed Web of Science ®Google Scholar
• Kayaw M, Toshizumi M, Tuchiya K, et al. Atheroprotetive effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol Sin. 2004; 25: 977–85.
   Google Scholar
• Carr Ac, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol. 2000; 20: 1716–23.
   PubMed Web of Science ®Google Scholar
• Chen J, Mehta JL, Haider N, et al. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res. 2004; 94: 370–6.
   PubMed Web of Science ®Google Scholar
• Ricci R, Sumara G, Sumara I, et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science. 2004; 306: 1558–61.
   PubMed Web of Science ®Google Scholar
• Wong BC, Jiang XH, Lin MC, et al. Cyclooxygenase- 2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. Gastroenterology. 2004; 126: 136–47.
   Google Scholar
• Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol. 2004; 173: 2011–22.
   PubMed Web of Science ®Google Scholar
• Lucas, R, Warner TD, Vojnovic I, et al. Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. FASEB J. 2005; 19: 635–7.
   PubMed Web of Science ®Google Scholar
• Sang N, Zhang J, Chen C. Prostaglandin E2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates hippocampal inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol. 2006; 572: 735–45.
   Google Scholar
• Tang HY, Shih A, Cao HJ, et al. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol Cancer Ther. 2006; 5: 2034–42.
   PubMed Web of Science ®Google Scholar
• Lin HY, Lansing L, Merillon JM, et al. Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J. 2006; 20: 1742–4.
   PubMed Web of Science ®Google Scholar
• Mercer J, Figg N, Stoneman V, et al. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ Res. 2005; 96: 667–74.
   PubMed Web of Science ®Google Scholar
• Mercer J, Bennett M. The Role of p53 in Atherosclerosis. Cell Cycle. 2006; 5: 1907–9.
   PubMed Web of Science ®Google Scholar
• Sihi A, Zhang S, Cai HJ, et al. Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-?. Mol Cancer Ther. 2004; 3: 1355–63.
   Google Scholar